Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI, Tsu-Yi Chao, T. Chao, C. Chiu, Y. Lu, H. Shiah, Y. Wu, G. Gerald Fetterly, N. Hung, D.L. Cutler, R. Kwan, D. Douglas Kramer, W. Chan, T. Hung

Research output: Contribution to journalArticle

Abstract

Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.
Original languageEnglish
JournalAnnals of Oncology
Publication statusPublished - Oct 21 2018

Fingerprint

Paclitaxel
Breast Neoplasms
Poisons
Neoplasms
Therapeutics

Cite this

Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients. / DAI, M.; Chao, Tsu-Yi; Chao, T.; Chiu, C.; Lu, Y.; Shiah, H.; Wu, Y.; Gerald Fetterly, G.; Hung, N.; Cutler, D.L.; Kwan, R.; Douglas Kramer, D.; Chan, W.; Hung, T.

In: Annals of Oncology, 21.10.2018.

Research output: Contribution to journalArticle

DAI, M, Chao, T-Y, Chao, T, Chiu, C, Lu, Y, Shiah, H, Wu, Y, Gerald Fetterly, G, Hung, N, Cutler, DL, Kwan, R, Douglas Kramer, D, Chan, W & Hung, T 2018, 'Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients', Annals of Oncology.
DAI, M. ; Chao, Tsu-Yi ; Chao, T. ; Chiu, C. ; Lu, Y. ; Shiah, H. ; Wu, Y. ; Gerald Fetterly, G. ; Hung, N. ; Cutler, D.L. ; Kwan, R. ; Douglas Kramer, D. ; Chan, W. ; Hung, T. / Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients. In: Annals of Oncology. 2018.
@article{c37e951a06c9408f9c3697e058b3a3b8,
title = "Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients",
abstract = "Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.",
author = "M. DAI and Tsu-Yi Chao and T. Chao and C. Chiu and Y. Lu and H. Shiah and Y. Wu and {Gerald Fetterly}, G. and N. Hung and D.L. Cutler and R. Kwan and {Douglas Kramer}, D. and W. Chan and T. Hung",
year = "2018",
month = "10",
day = "21",
language = "English",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

AU - DAI, M.

AU - Chao, Tsu-Yi

AU - Chao, T.

AU - Chiu, C.

AU - Lu, Y.

AU - Shiah, H.

AU - Wu, Y.

AU - Gerald Fetterly, G.

AU - Hung, N.

AU - Cutler, D.L.

AU - Kwan, R.

AU - Douglas Kramer, D.

AU - Chan, W.

AU - Hung, T.

PY - 2018/10/21

Y1 - 2018/10/21

N2 - Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

AB - Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.

M3 - Article

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -